Affiliation:
1. Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA
Abstract
Learning Objectives
Evaluate the evidence of improved overall survival with the use of sorafenib for the treatment of unresectable hepatocellular carcinoma. Recognize the potential for drug interactions for sorafenib with concurrent use of drugs that can induce or inhibit CYP3A4. Recognize side effects of sorafenib therapy including elevated blood pressure, diarrhea, fatigue, skin rash/ desquamation, hand–foot skin reaction, alopecia, and nausea, and counsel your patients about side effect management.
This article is available for continuing medical education credit at CME.TheOncologist.com.
Publisher
Oxford University Press (OUP)
Cited by
170 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献